Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
<p>Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.</p>
Збережено в:
| Автор: | |
|---|---|
| Інші автори: | , , , , , , , , , , , , , , , , , , , , |
| Опубліковано: |
2025
|
| Предмети: | |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Резюме: | <p>Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.</p> |
|---|